Global Chronic Obstructive Pulmonary Disease Market Insights Forecasts to 2030

• The Chronic Obstructive Pulmonary Disease market was valued at USD 18.20 billion in 2021.
• The market is growing at a CAGR of 8.2% from 2022 to 2030
• The global Chronic Obstructive Pulmonary Disease market is expected to reach USD 35.90 billion by 2030
• Asia Pacific is expected to grow the fastest during the forecast period

The global Chronic Obstructive Pulmonary Disease market is expected to reach USD 35.90 billion by 2030, at a CAGR of 8.2% during the forecast period 2022 to 2030.

Market Overview

Airflow from the lungs is obstructed by Chronic Obstructive Pulmonary Disorder (COPD), a chronic inflammatory lung condition. Wheezing, coughing up phlegm, and trouble breathing are all signs of COPD. It is typically brought on by prolonged exposure to irritant chemicals and particulates, frequently from cigarette smoke. Those with COPD may develop heart disease, lung cancer, and a range of other medical disorders. Emphysema and chronic bronchitis are two common illnesses that cause COPD. Inflammation of the bronchial tubes' linings, which transport air to and from the lungs' alveoli, is known as chronic bronchitis. Daily coughing and mucus production are used to diagnose it. Emphysema is a medical disorder in which the bronchioles, the smallest air channels in the lungs, are destroyed as a result of exposure to irritant gases and cigarettes. Although being a chronic condition, COPD is curable with the right care and management. Exposure to tobacco smoke, asthmatic patients, occupational chemical exposure, exposure to fuel-burning fumes, and a genetic condition called alpha-1-antitrypsin deficiency are all risk factors for COPD.

Report Coverage

This research report categorizes the market for Chronic Obstructive Pulmonary Disease market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Chronic Obstructive Pulmonary Disease market. Recent market developments and competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the Chronic Obstructive Pulmonary Disease market.

Driving Factors

One of the key factors anticipated to accelerate the growth and demand of the chronic obstructive pulmonary disease market is the increase in COPD cases among the global population. Also, during the course of the forecast period, it is anticipated that rising cigarette consumption among young people and rising public knowledge of the benefits of using generic medications would both contribute to the expansion of the global market. Also, rising healthcare spending and increased public awareness in undeveloped and developing nations are projected to support the market's expansion. These factors include the provision of facilities for treating chronic obstructive pulmonary disease in developing nations. Moreover, one of the important factors anticipated to propel the growth of the chronic obstructive pulmonary disease market is the rise in R&D spending by the government and major players.

Restraining Factors

While the lack of public awareness and understanding of the symptoms and indications of COPD can pose a threat to the market's expansion, the strict government restrictions and high cost of chronic obstructive pulmonary disease treatment are anticipated to restrain the growth of the COPD market.

Market Segmentation

• In 2021, the Chronic Bronchitis segment is dominating the market with largest market share over the forecast period.

On the basis of COPD Type, the global Chronic Obstructive Pulmonary Disease Market is segmented into  Chronic Bronchitis and Emphysema. Among these, the chronic bronchitis segment is dominating the market with largest market share over the forecast period due to an increase in cigarette usage, increased industrialization, and the production of toxic chemicals into the environment, chronic bronchitis incidence and prevalence are on the rise globally. These variables have influenced the rise in chronic bronchitis cases, which is propelling this market's expansion.

• In 2021, the Drugs segment accounted the highest market share over the forecast period.

Based on the treatment type, the global chronic obstructive pulmonary disease market is segmented into Drugs, Oxygen Therapy, Surgery, and Others. Among these, the drugs segment accounted the highest market share over the forecast period. The market expansion of this segment has been further fueled by the rising usage of medicines as the first line of treatment for COPD to ease breathing by opening up airways.

• In 2021, the Hospitals segment is dominating the market with the largest market share over the forecast period.

On the basis of end user, the global Chronic Obstructive Pulmonary Disease Market is segmented into Hospitals, Clinics, Homecare Settings, and Others. Among these, the hospitals segment is dominating the market with the largest market share over the forecast period because there are more people suffering from numerous chronic respiratory diseases and lifestyle disorders, and because people are becoming more aware of these diseases. Also, the presence of highly skilled healthcare professionals, increased purchasing power, and the availability of various diagnostic and treatment facilities are promoting the expansion of the hospital segment of the global chronic obstructive pulmonary disease market.

Regional Segment Analysis of the Chronic Obstructive Pulmonary Disease Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is dominating the market with the largest market share over the forecast period.

In 2020, North America had the greatest revenue share in the global market for chronic obstructive pulmonary disease, and it is anticipated that it will continue to hold this position during the forecast period. The increased investment in R&D efforts for the creation of novel medications for the treatment of various chronic respiratory diseases as well as lifestyle conditions is primarily responsible for the revenue rise in the North American market. The COPD Market in the area is also being boosted by a number of important factors, including an increase in the incidence and prevalence of chronic respiratory disorders, technological advancements, expanding healthcare sectors, and a large presence of top market players.

Recent Developments

• In July 2021, AstraZeneca's Biologics License Application (BLA) for tezepelumab for the treatment of asthma was approved by the US FDA and given Priority Review. Tezepelumab is being developed by AstraZeneca and Amgen Inc.

• In June 2021, in order to evaluate the effectiveness and safety of two doses of CHF6001 (Tanimilast) as an addition to maintenance triple treatment in patients with chronic obstructive pulmonary disease, Chiesi Farmaceutici SpA carried out a Phase III clinical trial of the PILASTER research.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global Chronic Obstructive Pulmonary Disease market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• AstraZeneca
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline plc
• Novartis AG
• CHIESI Farmaceutici SpA
• Sunovion Pharmaceuticals Inc
• Teva Pharmaceutical Industries Ltd
• Mylan N.V.
• Orion Corporation
• Merck & Co., Inc.
• Grifols
• S.A.
• Abbott
• F. Hoffmann-La Roche Ltd.
• Vectura Group plc
• Pfizer Inc.
• Alkermes
• Mylan N.V
• Almirall
• Genentech, Inc.
• Biogen
• Astellas Pharma Inc.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at global, regional, and country levels from 2021 to 2030. Spherical Insights has segmented the global Chronic Obstructive Pulmonary Disease market based on the below-mentioned segments:

Chronic Obstructive Pulmonary Disease Market, By COPD

• Chronic Bronchitis
• Emphysema

Chronic Obstructive Pulmonary Disease Market, By Treatment Type

• Drugs
• Oxygen Therapy
• Surgery
• Others

Chronic Obstructive Pulmonary Disease Market, By End User

• Hospitals
• Clinics
• Homecare Settings
• Others

Chronic Obstructive Pulmonary Disease Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa